TCTR20210708004招募中1 期
A Multicenter, Randomized, Double-blind, Controlled trial of effects of using intravenous metoclopramide to increase mucosal visualization during endoscopy in patients with acute upper gastrointestinal bleeding
avamindradhiraj university Research Fund0 个研究点目标入组 300 人开始时间: 2021年7月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 95 Years（—）
- 性别
- All
入选标准
- •Out-patient present in emergency department or in-patient has new inset upper gastrointestinal bleeding and received endoscopy within 24 hours of presentation or visited hospital
排除标准
- •History of metoclopramide allergy
- •Underlying disease of psychiatric problem, Parkinson disease, Abnormal movement, Chronic kidney disease more than stage 4
- •Pregnancy or breast feeding
- •Family history of Tardive dyskinesia
研究者
相似试验
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCnresectable Stage III Non-small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003265-34-ESMerck KGaA350
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCnresectable Stage III Non-small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003265-34-DEMerck KGaA160
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCnresectable Stage III Non-small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003265-34-HUMerck KGaA160
已完成
2 期
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancerlung cancerNon-small cell lung cancerNL-OMON52935Merck20
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCEUCTR2018-003265-34-BEMerck KGaA160